Matoke Holdings Ltd (MHL) is a British biotechnology SME developing its proprietary Reactive Oxygen® technology as a ground-breaking antimicrobial for wound care and infection control. Our mission is to find effective, safe, scalable and practical solutions which can be delivered in a short timescale to meet the global threat of antibiotic resistance and improve patient outcomes/ lives. Our experienced management team and exceptional scientific leaders are working in partnership with world-leading researchers at British universities and teaching hospitals to develop innovative antimicrobial products, both medicinal/pharmaceutical and medical device, from discovery through to manufacture, regulatory approval and early clinical use.
There is no investment information
No recent news or press coverage available for Matoke Holdings Ltd.